Navigation Links
Immtech Investor Conference Call Scheduled for February 11, 2008
Date:2/6/2008

release contains forward-looking statements regarding Immtech's business, including the future prospects for PCP. Except for historical information, the matters discussed in this press release are forward-looking statements and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to the following: (i) Immtech's ability to develop commercially viable products; (ii) Immtech's ability to achieve profitability; (iii) Immtech's ability to retain key personnel; (iv) the ability of Immtech's scientists and collaborators to discover new compounds; (v) the availability of additional research grants; (vi) Immtech's ability to obtain regulatory approval of its drug candidates, including PCP; (vii) the success of Immtech's clinical trials; (viii) Immtech's dependence upon and contractual relationship with partners; (ix) Immtech's ability to manufacture or to contract with a third party to manufacture its drug candidates at reasonable costs; (x) Immtech's ability to protect its intellectual property; (xi) competition and alternative technologies; (xii) Immtech's ability to obtain reimbursement from third party payers for any product it commercializes; and (xiii) Immtech's potential exposure to significant product liability.

Additional risks are discussed in Immtech's current filings with the Securities and Exchange Commission. Although Immtech believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and Immtech undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.


'/>"/>
SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine
2. Immtech to Present at The Bank of Montreal Healthcare Conference
3. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
5. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
6. PharmAthene to Present at the BIO CEO & Investor Conference 2008
7. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
8. Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12
9. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
10. Rigel to Present at BIO CEO & Investor Conference
11. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014  InterMune, Inc. (NASDAQ: ... second quarter 2014 financial results at the close of ... conference call and webcast will be hosted by InterMune ... Interested investors and others may participate in the ... (international), conference ID#21728775. A replay of the webcast and teleconference ...
(Date:7/26/2014)... July 26, 2014 Canada Endoscopy ... market data on the Canada Endoscopy Visualization Systems ... US dollars, volume (in units) and average prices ... Endoscopy Visualization Systems, Mid-Range Endoscopy Visualization Systems and ... at http://www.marketresearchreports.biz/analysis/213254 . , The report also ...
(Date:7/25/2014)... new study by researchers from the University of ... nanosystems function, unlocking the potential to create new ... which has been published in the prestigious academic ... novel laser technique to examine in rich detail ... small cluster containing an acetylene molecule and a ...
(Date:7/25/2014)... PA (PRWEB) July 25, 2014 The ... Call for Topics for Conferee Networking. These two-hour sessions ... interests to meet and resolve problems, discuss new techniques, ... The deadline to submit a topic for consideration is ... pittcon.org . The Conferee Networking committee will review ...
Breaking Biology Technology:InterMune to Release Second Quarter Financial Results on August 6 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2
... DIEGO, Nov. 2, 2010 Ardea Biosciences, Inc. (Nasdaq: ... been awarded a $733,438 grant from the Department of ... Patient Protection and Affordable Care Act.  Ardea submitted three ... active development, for expenses incurred during 2009 and 2010. ...
... 2010 Vaccinex, Inc. announced today that it has ... under the Qualifying Therapeutic Discovery Project (QTDP) Program to ... monoclonal antibodies, VX15, VX5 and VX35.  The QTDP grant ... by the U.S. Department of Health and Human Services ...
... ... ... var shortURL = ""; BitlyCB.alertResponse = ... the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key in first_result) ...
Cached Biology Technology:Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act 2Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act 3NEURO-BIOTECH CORPORATION: Updates and latest developments 2NEURO-BIOTECH CORPORATION: Updates and latest developments 3NEURO-BIOTECH CORPORATION: Updates and latest developments 4NEURO-BIOTECH CORPORATION: Updates and latest developments 5NEURO-BIOTECH CORPORATION: Updates and latest developments 6NEURO-BIOTECH CORPORATION: Updates and latest developments 7NEURO-BIOTECH CORPORATION: Updates and latest developments 8NEURO-BIOTECH CORPORATION: Updates and latest developments 9
(Date:7/27/2014)... largest prevalence studies to date, researchers from the U.K. ... the hepatitis C virus (HCV). Findings published in Hepatology, ... of Liver Diseases, indicate that genotype 1 is the ... of which one-third reside in East Asia. Genotype 3, ... most prevalent, followed by genotypes 2, 4, 6, and ...
(Date:7/27/2014)... the potential for global climate change to cut food ... ignored the interactions between increasing temperature and air pollution ... crops. , A new study involving researchers at MIT ... that policymakers need to take both warming and air ... study looked in detail at global production of four ...
(Date:7/27/2014)... patients, scientists have identified more than two dozen ... six that had not been previously reported. The ... partially funded by the National Institutes of Health ... laboratories. , "Unraveling the genetic underpinnings of Parkinson,s ... in this complex disease, and hopefully, may one ...
Breaking Biology News(10 mins):Hepatitis C virus genotype 1 is most prevalent worldwide 2Study: Climate change and air pollution will combine to curb food supplies 2Study: Climate change and air pollution will combine to curb food supplies 3NIH scientists find 6 new genetic risk factors for Parkinson's 2
... temperatures and the ability to conserve water for long periods ... arid parts of the world. But is this global ... the open-access, peer-reviewed journal PLoS ONE April 9, ... Haifa, Israel now show that this is indeed the case, ...
... Calif., April 9, 2009Scientists at Burnham Institute for Medical ... (UC San Diego) School of Medicine have demonstrated in ... the immune system when encapsulated in polytetrafluorethylene (PTFE). The ... 1 diabetes, was published online on April 8 in ...
... if you stare at the downward motion of a waterfall ... appear to drift upward. MIT neuroscientists have found that ... visual perception but also in our tactile perception, and that ... you feel the world can actually change how you see ...
Cached Biology News:Scorpion biodiversity 2Device protects transplanted pancreatic cells from the immune system 2MIT: How you feel the world impacts how you see it 2
... on the ease of use and flexibility of the ... introduces the BDTM LSR II. The BD LSR ... in a benchtop analyzer. Free up your high-performance ... UV laser to the BD LSR II. The BD ...
... real-time PCR detection system uses a fixed ... nm) and two photomultiplier tubes for 2-color ... 2 system is built on an DNA ... gradient feature. This item includes the thermal ...
Fingerprinting II Basic software is used for analyzing fingerprint sample types (electrophoretic gels, HPLC and other chromatographic patterns, spectrophotometric and densitometric curves)....
Fingerprinting II database sharing tools is an optional module for the Fingerprinting II Basic software package that enables peer-to-peer data exchange over the internet and provides external databas...
Biology Products: